Expanding Existing Jōban Plant Facilities to Meet Growing Glycine Demand
First written in FY2023-Q1. 2 of 6 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AchievedAnnual report
「Amino acid production equipment completed in June this year」
The company disclosed the June completion of the amino acid production equipment at the Tokiwa Plant, for which approximately ¥4 billion had been invested and which had been scheduled for completion in March 2025. The completion is also reflected in a decrease in construction in progress and increases in buildings, machinery and equipment, marking the completion milestone of the equipment expansion plan. - FY2025-H1AdvancedAnnual report
「Cash used in investing activities decreased by ¥1,245 million (compared with a decrease of ¥333 million in the previous interim accounting period). This was mainly attributable to ¥1,196 million in payments for the acquisition of property, plant and equipment.」
In connection with the expansion of existing equipment at the Tokiwa Plant to meet glycine demand, the company recorded ¥1,196 million in payments for the acquisition of property, plant and equipment during the interim period. Construction in progress also increased from ¥1,176 million at the end of the previous fiscal year to ¥2,216 million, indicating progress on the capital investment scheduled for completion in March 2025. - FY2024AdvancedAnnual report
「During the fiscal year, the company made capital investments of ¥1,833 million, including intangible fixed assets, to improve quality and expand production facilities. Major facilities completed during the fiscal year included the acquisition and renewal of amino acid production equipment totaling ¥1,358 million. Tokiwa Plant Amino acid equipment Approximately ¥4 billion Approximately ¥1.3 billion Internal funds and borrowings July 2022 March 2025 Increase in glycine production capacity」
Of the approximately ¥4 billion amino acid equipment investment decided on to meet glycine demand, approximately ¥1.3 billion had been paid. The company disclosed the completion of ¥1,358 million in acquisitions and renewals of amino acid production equipment during the fiscal year. Completion is scheduled for March 2025. - FY2023-Q3RestatedAnnual report
「Against this backdrop, the Company is working toward the realization of a sustainable society while assessing market trends and demand, responding flexibly, overcoming and resolving key issues, and strengthening its management foundation, including making a corporate decision last July on a large-scale capital investment.」
The company has reconfirmed its decision last July to make a major investment in expanding existing equipment to meet glycine demand. No progress beyond the previous disclosure, such as the investment amount or scheduled completion, has been indicated. - FY2023-Q2RestatedAnnual report
「Under these conditions, the company is working to strengthen its management foundation and achieve a sustainable society by assessing market trends and demand, responding flexibly, and overcoming and resolving key challenges, including by deciding in July to make a major investment in amino acid production equipment.」
The company has reconfirmed its decision in July to make a major investment in expanding existing equipment at the Tokiwa Plant to meet glycine demand. No new progress beyond the previous disclosure, such as the investment amount or completion schedule, has been indicated. - FY2023-Q1First statedAnnual report
「As demand for glycine, one of the company’s amino acid products, has increased, the company will invest in expanding existing equipment at the Tokiwa Plant in Iwaki, Fukushima Prefecture, to establish a higher-capacity production system. Investment amount: approximately ¥4 billion. Equipment: expansion of existing equipment, including raw material tanks, deionized water production equipment, centrifuges, dryers, packaging equipment and an ISO Class 8 cleanroom. Products: amino acids (glycine). Scheduled start of construction: July 2022. Scheduled completion: March 2025.」
At a meeting of the Board of Directors held on 19 July 2022, the company decided to invest in expanding existing equipment at the Tokiwa Plant to meet rising demand for glycine. The investment is approximately ¥4 billion, with construction scheduled to begin in July 2022 and completion scheduled for March 2025. The plan includes expanding raw material tanks, deionized water production equipment, centrifuges, dryers, packaging equipment and an ISO Class 8 cleanroom.